FDA CRL for TrenibotE Adds to Aesthetics Headwinds, but Core Thesis Unchanged

What happened

FDA issued a Complete Response Letter for AbbVie's fast-acting neurotoxin TrenibotE citing manufacturing issues, with no safety or efficacy concerns. This delays a potential new product for the aesthetics franchise, which is already under pressure with FY2025 sales down 6.1% and Juvederm declining double-digits. The DeepValue report had flagged aesthetics as a swing factor needing stabilization; the CRL makes achieving the $5B 2026 guide more challenging. However, the core investment thesis relies on Skyrizi and Rinvoq, which together represent ~42% of revenue and are on track for $34.5B in immunology sales in 2026. The CRL does not alter the fundamental immunology growth story, but it reinforces the need for patience as aesthetics headwinds persist.

Implication

The TrenibotE delay adds to existing aesthetics overhangs but does not break the thesis, as the primary value driver remains Skyrizi/Rinvoq execution. Investors should continue to monitor immunology share capture and reaffirmation of the 2026 framework. Any meaningful stock impact from aesthetics is likely limited given its smaller revenue contribution (~8%).

Thesis delta

No material shift; the CRL reinforces existing concerns about aesthetics but does not change the core thesis centered on immunology growth. The WAIT rating remains appropriate pending proof of Skyrizi/Rinvoq share capture.